Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.
Precision medicine is advancing quicker than ever before in dermatology, and this is of utmost importance for certain complex dermatologic conditions that have proven difficult to understand and manage, said Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento.
Transcript
What are your thoughts on the future of therapeutic innovation in dermatology?
I'm just excited about all of the therapies that are coming into dermatology. I think it's a very exciting time, where precision medicine is really starting to happen. We're talking about personalized therapies for certain types of diseases. And I think the immunology is really catching up to what we have in the clinic. And that's been in part due to huge research advances and technological advances where what we couldn't do 5 years ago, even a couple of years ago, we're starting to do today. So, it's a really exciting time.
We're advancing medicine quicker than we have in the past where research was primarily performed or done in silos. Small groups, studying things in their lab with groups of 8 to 20 people, but now we're in big medicine where large companies and organizations are looking at big data. They're coupling with machine learning and artificial intelligence.
So, I think we can start to tackle some of these really complex medical dermatologic conditions, and really start to tease out subtleties that we couldn't look at or understand what we were looking at with a small microscope, but now we've got the power to start to tease out how do the genetics really play a role with environment, etc. So, I just think this is the beginning of medicines that are going to be really targeted and highly effective, and it's just an exciting time to be in medical dermatology right now.
Hospital Stays and Probable Dementia as Predictors of Relocation to Long-Term Care Facilities
October 22nd 2024This article explores late-life relocations in patients with dementia, hospital stays, and their implications for health care policy, geriatric care, and future research priorities.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More